Abstract PS6-35: Real world outcomes in elderly women with HER2 positive advanced breast cancer

摘要: BackgroundThe development of anti-human epidermal growth factor receptor 2 (HER2) therapies has significantly improved disease outcomes in patients with HER2-positive advanced breast cancer (ABC). However, elderly are persistently under-represented clinical trials, only 2.4% aged ≥75 years the pivotal CLEOPATRA study. Despite a lack research addressing treatment patients, age at diagnosis is associated greater likelihood receiving no initial systemic therapy for de novo metastatic cancer. Studies have also shown that older women diagnosed poorer prognosis and shorter life expectancy. We examined patterns an (defined as ≥70) ‘real world’ Australian population. MethodsData was extracted from Treatment Advanced Breast Cancer Patient (TABITHA) multi-site registry, stratified according to ( ResultsWe identified 319 including 67 (21%) ≥70 years. Older were more likely Eastern Cooperative Oncology Group performance status ≥2 (16% vs 3%; p ConclusionElderly ABC demonstrated chemotherapy durations, overall survival, increased rates adverse events despite having similar characteristics patterns. Prospective studies required improve HER2 positive Citation Format: Nicole Evans, Angelyn Anton, Rachel Wong, Sheau Wen Lok, Richard De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Louise Nott, Gary Richardson, Ian M Collins, Javier Torres, Frances Barnett, Peter Gibbs, Bianca Devitt. Real world [abstract]. In: Proceedings 2020 San Antonio Virtual Symposium; Dec 8-11; Antonio, TX. Philadelphia (PA): AACR; Res 2021;81(4 Suppl):Abstract nr PS6-35.